Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Adaptive Biotechnologies Corp

Healthcare US ADPT

16.9USD
-1.18(6.53%)

Last update at 2026-06-05T20:00:00Z

Day Range

16.6818.29
LowHigh

52 Week Range

7.1620.76
LowHigh

Fundamentals

  • Previous Close 18.08
  • Market Cap2245.05M
  • Volume2158923
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-39.29000M
  • Revenue TTM276.98M
  • Revenue Per Share TTM1.83
  • Gross Profit TTM 205.62M
  • Diluted EPS TTM-0.39

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -59.45700M -159.59500M -225.30400M -200.36800M -207.29800M
Minority interest -0.04200M 0.10M 0.07M 0.18M -0.01900M
Net income -59.49900M -159.49200M -225.25000M -142.46400M -205.61100M
Selling general administrative 72.70M 72.81M 83.93M 88.53M 74.50M
Selling and marketing expenses 94.57M 84.76M 88.58M 95.60M 95.47M
Gross profit 205.62M 106.88M 94.72M 127.40M 105.04M
Reconciled depreciation 17.83M 19.26M 22.12M 20.92M 13.95M
Ebit -47.67900M -148.01500M -211.50400M -200.18600M -208.96600M
Ebitda -29.84600M -128.75900M -189.27300M -194.43100M -207.26700M
Depreciation and amortization 17.83M 19.26M 22.23M 5.75M 1.70M
Non operating income net other - - - 4.06M 1.67M
Operating income -57.12300M -162.54900M -227.03500M -200.18600M -208.96600M
Other operating expenses 334.10M 341.51M 397.31M 385.49M 363.31M
Interest expense 11.78M 11.58M 13.80M 4.24M 1.67M
Tax provision - - - - 0.00000M
Interest income 9.44M 14.53M 13.52M 4.06M 1.67M
Net interest income -2.33400M 2.95M -0.85300M -0.18200M 1.67M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - -0.05400M -57.90400M -1.68700M
Total revenue 276.98M 178.96M 170.28M 185.31M 154.34M
Total operating expenses 262.74M 269.43M 321.76M 327.58M 314.01M
Cost of revenue 71.36M 72.08M 75.55M 57.91M 49.30M
Total other income expense net -2.33400M 2.95M 1.73M -0.18200M 1.67M
Discontinued operations - - - - -
Net income from continuing ops -59.45700M -159.59500M -196.00600M -200.36800M -207.29800M
Net income applicable to common shares - - - -200.19100M -207.27900M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 512.74M 539.38M 661.13M 856.62M 923.34M
Intangible assets 1.73M 3.42M 5.13M 6.83M 8.53M
Earning assets - - - - -
Other current assets 13.02M 11.29M 10.37M 9.44M 13.02M
Total liab 287.74M 336.89M 352.86M 392.52M 319.24M
Total stockholder equity 218.79M 202.71M 308.40M 464.17M 603.99M
Deferred long term liab - - - - -
Other current liab 24.69M 24.68M 22.28M 28.36M 24.98M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -1363.32300M -1303.82400M -1144.33200M -919.08200M -718.89100M
Other liab - - - 183.96M 98.75M
Good will 118.97M 118.97M 118.97M 118.97M 118.97M
Other assets - - - 4.46M 3.01M
Cash 70.50M 47.92M 65.06M 90.03M 139.06M
Cash and equivalents - - - - -
Total current liabilities 89.92M 98.05M 88.02M 109.79M 113.81M
Current deferred revenue 45.19M 55.69M 48.63M 64.11M 80.46M
Net debt 210.09M 41.47M 164.37M 17.97M -27.32500M
Short term debt 13.56M 10.24M 9.38M 9.23M 5.05M
Short long term debt - - - - -
Short long term debt total 280.58M 89.39M 229.43M 108.00M 111.74M
Other stockholder equity 1581.85M 1506.35M 1452.50M 1387.35M 1324.01M
Property plant equipment - - - 83.45M 85.26M
Total current assets 300.19M 283.75M 410.19M 562.15M 402.75M
Long term investments 13.23M 33.66M - 0.00000M 217.15M
Net tangible assets - - - 338.37M 476.49M
Short term investments 156.49M 174.37M 281.34M 408.17M 214.00M
Net receivables 50.37M 41.73M 38.97M 40.06M 17.41M
Long term debt - - - - -
Inventory 9.82M 8.44M 14.45M 14.45M 19.26M
Accounts payable 6.47M 7.26M 7.72M 8.08M 3.31M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - -0.06700M 0.11M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.25M 0.17M 0.21M -4.11600M -1.13700M
Additional paid in capital - - - - -
Common stock total equity - - - 0.01M 0.01M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -919.08200M -718.89100M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.21M 5.18M -1.53700M 4.46M 3.01M
Deferred long term asset charges - - - - -
Non current assets total 212.55M 255.62M 250.95M 294.47M 520.60M
Capital lease obligations 79.15M 89.39M 98.77M 108.00M 111.74M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 40.91M 77.79M 28.90M 2.90M 242.96M
Change to liabilities - - - 7.11M 3.94M
Total cashflows from investing activities 37.95M 77.79M 129.65M 2.90M 181.21M
Net borrowings - - - - -
Total cash from financing activities 30.40M 0.24M 2.25M 132.26M 27.15M
Change to operating activities - - - -0.33000M 9.53M
Net income -59.49900M -159.59500M -225.25000M -200.36800M -207.29800M
Change in cash 22.37M -17.17900M -24.96600M -48.77500M 15.63M
Begin period cash flow 50.82M 68.00M 90.03M 141.20M 125.57M
End period cash flow 73.18M 50.82M 65.06M 92.43M 141.20M
Total cash from operating activities -45.98600M -95.21200M -156.32400M -183.94500M -192.72700M
Issuance of capital stock - - - 0.00000M 0.00000M
Depreciation 17.83M 19.26M 22.23M 20.92M 13.95M
Other cashflows from investing activities - - -0.00000M - -
Dividends paid - - - - -
Change to inventory -0.99800M 1.94M -2.83800M 0.82M -5.20000M
Change to account receivables -8.64600M -3.74400M 2.03M -22.64800M -7.36200M
Sale purchase of stock - - - 7.89M 26.72M
Other cashflows from financing activities 30.40M 0.24M 2.25M 124.38M 27.15M
Change to netincome - - - 56.44M 43.17M
Capital expenditures 2.96M 3.66M 10.70M 16.35M 61.75M
Change receivables - - - -22.64800M -7.36200M
Cash flows other operating - - - -46.96100M -41.16600M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -48.77500M 15.63M
Change in working capital -57.76700M -17.45400M -46.18300M -71.54600M -56.81600M
Stock based compensation 51.48M 53.61M 62.91M 55.48M 43.25M
Other non cash items 19.80M 8.97M 92.88M 11.57M 6.95M
Free cash flow -48.94500M -98.87600M -167.02100M -200.29400M -254.47300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ADPT
Adaptive Biotechnologies Corp		 -1.18 6.53% 16.90 - - 8.11 10.19 7.52 -0.9991
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Adaptive Biotechnologies Corp

1165 Eastlake Avenue East, Seattle, WA, United States, 98109

Key Executives

Name Title Year Born
Mr. Chad M. Robins M.B.A, M.B.A. Co-Founder, CEO & Chairman 1974
Ms. Julie Rubinstein Pres 1972
Dr. Harlan S. Robins Ph.D. Co-Founder & Chief Scientific Officer 1973
Mr. Nitin Sood Chief Commercial Officer of MRD NA
Mr. Christopher Carlson Ph.D. Founder NA
Mr. Tycho W. Peterson Chief Financial Officer NA
Dr. Mark Adams Ph.D. Chief Operating Officer 1967
Mr. Kyle Piskel Principal Accounting Officer 1984
Yi Zhou Chief Technical Officer NA
Karina Calzadilla VP of Investor Relations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.